Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010–2017
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Aim: To describe population‐level time trends in prescribing patterns of type 2 diabetes therapy, and in short‐term clinical outcomes (glycated haemoglobin [HbA1c], weight, blood pressure, hypoglycaemia and treatment discontinuation) after initiating new therapy. Materials and methods: We studied 81 532 people with type 2 diabetes initiating a first‐ to fourth‐line drug in primary care between 2010 and 2017 inclusive in United Kingdom electronic health records (Clinical Practice Research Datalink). Trends in new prescriptions and subsequent 6‐ and 12‐month adjusted changes in glycaemic response (reduction in HbA1c), weight, blood pressure and rates of hypoglycaemia and treatment discontinuation were examined. Results: Use of dipeptidyl peptidase‐4 inhibitors as second‐line therapy near doubled (41% of new prescriptions in 2017 vs. 22% in 2010), replacing sulphonylureas as the most common second‐line drug (29% in 2017 vs. 53% in 2010). Sodium‐glucose co‐transporter‐2 inhibitors, introduced in 2013, comprised 17% of new first‐ to fourth‐line prescriptions by 2017. First‐line use of metformin remained stable (91% of new prescriptions in 2017 vs. 91% in 2010). Over the study period there was little change in average glycaemic response and in the proportion of people discontinuing treatment. There was a modest reduction in weight after initiating second‐ and third‐line therapy (improvement in weight change 2017 vs. 2010 for second‐line therapy: −1.5 kg, 95% confidence interval [CI] −1.9, −1.1; P < 0.001), and a slight reduction in systolic blood pressure after initiating first‐, second‐ and third‐line therapy (improvement in systolic blood pressure change 2017 vs. 2010 range: −1.7 to −2.1 mmHg; all P < 0.001). Hypoglycaemia rates decreased over time with second‐line therapy (incidence rate ratio 0.94 per year, 95% CI 0.88, 1.00; P = 0.04), mirroring the decline in use of sulphonylureas. Conclusions: Recent changes in prescribing of therapy for people with type 2 diabetes have not led to a change in glycaemic response and have resulted in modest improvements in other population‐level short‐term clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · cited 1×
“24,37,38 A recent meta-analysis of randomized trials suggested that, in contrast to SGLT2-inhibitors and GLP-1 receptor agonists, there is no short-term mortality benefit with DPP-4 inhibitors.”
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“24,37,38 A recent meta-analysis of randomized trials suggested that, in contrast to SGLT2-inhibitors and GLP-1 receptor agonists, there is no short-term mortality benefit with DPP-4 inhibitors.”
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · cited 1×
“39 Given the recent changes in treatment guidelines to consider cardio-vascular risk when choosing therapy, 4 and the fact all three classes have now been prescribed in significant numbers for some years, an evaluation of recent time trends in microvascular and macrovascular complications would be…”
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Self-citationData Resource Profile: Clinical Practice Research Datalink (CPRD)
Herrett, E., Gallagher, A. M., Bhaskaran, K., Forbes, H., Mathur, R., van Staa, T., & Smeeth, L. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv098 · Cited by 2,667 · cited 1×
“CPRD is a population-representative database including demographic, clinical and prescription primary care records of patients.(13) Although CPRD includes full prescription records, no data on drug dispensation are available.”
Khunti, K., Davies, M., Majeed, A., Thorsted, B. L., Wolden, M. L., & Paul, S. K. (2015) · Diabetes Care · doi:10.2337/dc14-0920 · Cited by 356 · cited 1×
“19 Because of the low number of hypoglycaemia events captured in primary care we grouped data into biannual categories representing four distinct periods (2010-2011, 2012-2013, 2014-2015, 2016-2017).”
Mazidi, M., Rezaie, P., Gao, H., & Kengne, A. P. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004007 · Cited by 347
Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013
Lipska, K. J., Yao, X., Herrin, J., McCoy, R. G., Ross, J. S., Steinman, M. A., Inzucchi, S. E., Gill, T. M., Krumholz, H. M., & Shah, N. D. (2017) · Diabetes Care · doi:10.2337/dc16-0985 · Cited by 306
Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Quan, X., Ji, L., & Zhan, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.07.015 · Cited by 304 · cited 1×
“Newer agents, in particular SGLT2-inhibitors, have been associated with modestly lower blood pressure.(24-27) However whilst there were small improvements over time in blood pressure change with second to fourth-line therapy there were also”
Background
Cited by
Marx, N., Husain, M., Lehrke, M., Verma, S., & Sattar, N. (2022) · Circulation · doi:10.1161/circulationaha.122.059595 · Cited by 483
Self-citationOfori‐Asenso, R., Sahle, B. W., Chin, K. L., Mazidi, M., Ademi, Z., De Bruin, M. L., & Liew, D. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3350 · Cited by 44
Sumarsono, A., Everett, B. M., McGuire, D. K., Fonarow, G. C., Butler, J., Pandey, A., & Vaduganathan, M. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.3884 · Cited by 21
Pi, L., He, B., Fei, D., Shi, X., & Zhou, Z. (2024) · BMC Primary Care · doi:10.1186/s12875-024-02600-4 · Cited by 6
Metadata
- Authors
- Dennis, J. M., Henley, W. E., McGovern, A. P., Farmer, A. J., Sattar, N., Holman, R. R., Pearson, E. R., Hattersley, A. T., Shields, B. M., Jones, A. G., & on behalf of the MASTERMIND consortium
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2019-04-04
- Volume
- 21
- Issue
- 7
- Pages
- 1576-1584
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2919371810
- Cited by
- 85
- References
- 11
- FWCI
- 9.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.